Key regions: Australia, Brazil, United Kingdom, Europe, Canada
The Other Vaccines market in Northern Europe has been experiencing several developments in recent years.
Customer preferences: Customers in Northern Europe have been increasingly interested in vaccines that target a wide range of diseases. This has led to a growing demand for Other Vaccines, which are designed to prevent illnesses beyond the most common ones. Additionally, customers in the region have been placing a greater emphasis on the safety and efficacy of vaccines, leading to increased scrutiny of the development and testing processes.
Trends in the market: One of the most significant trends in the Other Vaccines market in Northern Europe has been the rise of combination vaccines. These products offer protection against multiple diseases in a single shot, which has become increasingly popular with customers who prefer a more efficient vaccination process. Additionally, there has been a growing focus on vaccines for emerging infectious diseases, such as Zika and Ebola. As the threat of these diseases continues to grow, there has been increased investment in the development of vaccines to prevent them.
Local special circumstances: Northern Europe has a highly developed healthcare infrastructure, which has allowed for the rapid adoption of new vaccines. Additionally, the region has a high level of public trust in vaccines and a strong commitment to public health, which has helped to drive demand for new products. However, the region also has a relatively small population compared to other regions, which can limit the market size for some products.
Underlying macroeconomic factors: The Northern European market is characterized by a high level of government involvement in healthcare, which can create both opportunities and challenges for vaccine manufacturers. On the one hand, government funding can support the development and distribution of new vaccines. On the other hand, government regulations can be complex and time-consuming, which can slow down the approval process for new products. Additionally, the region has a relatively high level of affluence, which can support higher prices for vaccines. However, this also means that customers may be more discerning in their purchasing decisions and demand greater value for their money.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
